01 9Gazyva/Gazyvaro
Main Therapeutic Indication : Oncology
Currency : USD
2019 Revenue in Millions : 569
2018 Revenue in Millions : 402
Growth (%) : 42
Main Therapeutic Indication : Oncology
Currency : USD
2020 Revenue in Millions : 704
2019 Revenue in Millions : 615
Growth (%) : 14
Main Therapeutic Indication : Oncology
Currency : USD
2021 Revenue in Millions : 730
2020 Revenue in Millions : 670
Growth (%) : 7
Main Therapeutic Indication : Oncology
Currency : USD
2022 Revenue in Millions : 798
2021 Revenue in Millions : 730
Growth (%) : 9
Main Therapeutic Indication : Oncology
Currency : USD
2023 Revenue in Millions : 941
2022 Revenue in Millions : 798
Growth (%) : 11
Main Therapeutic Indication : Hematology
Currency : USD
2024 Revenue in Millions : 1,002
2023 Revenue in Millions : 941
Growth (%) : 7
Main Therapeutic Indication : Oncology
Currency : USD
2016 Revenue in Millions : 194
2015 Revenue in Millions : 127
Growth (%) : 53
Main Therapeutic Indication : Oncology
Currency : USD
2017 Revenue in Millions : 295
2016 Revenue in Millions : 208
Growth (%) : 42
Main Therapeutic Indication : Oncology
Currency : USD
2018 Revenue in Millions : 394
2017 Revenue in Millions : 281
Growth (%) : 40%
